In phase I/II multi-center trial of CD19-CAR-CTL therapy in children with ALL conducted by Rossig et al., the Donor-Epstein-Barr-virus-specific cytotoxic T-cells (EBV-CTL) were transduced to the CD19-CAR. Here, CD19 is linked to acute lymphoblastic leukemia.